Global IBS Treatment Market Growth (Status and Outlook) 2025-2031

According to this study, the global IBS Treatment market size will reach US$ million by 2031.

Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.

Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year.

LPI (LP Information)' newest research report, the “IBS Treatment Industry Forecast” looks at past sales and reviews total world IBS Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected IBS Treatment sales for 2025 through 2031. With IBS Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world IBS Treatment industry.

This Insight Report provides a comprehensive analysis of the global IBS Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on IBS Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global IBS Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for IBS Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global IBS Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of IBS Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:
IBS-D
IBS-C
IBS-M

Segmentation by Application:
Hospitals
Clinics
Research Laboratories

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan (Ireland)
Sucampo Pharmaceuticals (U.S.)
Ironwood Pharmaceuticals (U.S.)
Astellas Pharma (Japan)
Bausch Health
Abbott Laboratories (U.S.)
Synergy Pharmaceuticals (U.S.)
Ardelyx (U.S.)
Nestle (Switzerland)
Sebela Pharmaceuticals (Ireland)
Probi (Sweden)
Alfasigma USA (Italy)
RedHill Biopharma (Israel)
AstraZeneca (U.K)
Ipsen (France)
Novartis (Switzerland)
Takeda Pharmaceutical Company (Japan)
Synthetic Biologics (U.S.)
Protagonist Therapeutics (U.S.)
Pfizer (U.S.)
Lexicon Pharmaceuticals (U.S.)
Innovate Biopharmaceuticals (U.S.)

Please note: The report will take approximately 2 business days to prepare and deliver. Show more